<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lederman, Lynne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Tan, Victoria P.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Rifaximin Effective in FD, Suggesting Intestinal Microbiota Involvement</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-08-07 10:43:03</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-14</style></pages><abstract><style  face="normal" font="default" size="100%">In this short small pilot study, the nonabsorbable antibiotic rifaximin relieves global dyspepsia symptoms, belching, and bloating in individuals with functional dyspepsia. The durability of symptom relief is unknown, and these promising results should be confirmed in a larger multicenter trial.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>